Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.
Purpose: To examine whether the potential benefits of low-dose aspirin outweigh the risks in people over age 70.
Purpose: To evaluate the safety, tolerability, and efficacy of AVP-923 (dxtromethorphan/qinidine) for the treatment of agitation in people with Alzheimer's disease.
Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.
Purpose: To evaluate the safety and tolerability of BIIB037 in people with prodromal or mild Alzheimer's disease.
Purpose: To determine the response of older adults with both depression and cognitive impairment to donepezil vs. placebo after treatment with antidepressants. The goal is improve cognition and delay conversion to dementia.
Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Purpose: To determine whether ELND005 is effective in treating symptoms of agitation and aggression in people with Alzheimer's disease.
Purpose: To evaluate the safety and efficacy of the experimental drug gantenerumab on cognition and functioning in people with prodromal (very early stage) Alzheimer's disease.
Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.
Purpose: To assess the efficacy and safety of MK-8931 as a possible treatment for Alzheimer's disease.
Purpose: To determine if difficulty with the sense of smell can predict conversion from mild cognitive impairment to Alzheimer's disease and track response to donepezil therapy.
Purpose: To evaluate the efficacy and safety of RO4602522 in people with moderate-stage Alzheimer disease who take donepezil or rivastigmine.
Purpose: To determine whether intensive blood pressure lowering will reduce the incidence of all-cause dementia, reduce the decline of global cognitive function in key specific domains, and show changes in brain structure.
Purpose: To determine the safety and efficacy of the experimental drug TRx0237 to treat people with mild Alzheimer's disease.
Purpose: To determine the safety and efficacy of the experimental drug TRx0237 to treat people with mild to moderate Alzheimer's disease.